Comprehensive analysis of the lncRNA‑associated competing endogenous RNA network in breast cancer

Wang,Jing‑Jing; Huang,Yue‑Qing; Song,Wei; Li,Yi‑Fan; Wang,Han; Wang,Wen‑Jie; Huang,Min

doi:10.3892/or.2019.7374

Comprehensive analysis of the lncRNA‑associated competing endogenous RNA network in breast cancer

Authors:
- Jing‑Jing Wang
- Yue‑Qing Huang
- Wei Song
- Yi‑Fan Li
- Han Wang
- Wen‑Jie Wang
- Min Huang
View Affiliations

Affiliations: Department of Oncology, Taizhou Hospital of Traditional Chinese Medicine, Taizhou, Jiangsu 225300, P.R. China, Department of General Practice, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu 215001, P.R. China, Department of Intervention and Vascular Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu 215001, P.R. China, Department of Oncology, Binzhou People's Hospital, Binzhou, Shandong 256600, P.R. China, Department of Oncology, Jining Cancer Hospital, Jining, Shandong 272000, P.R. China, Department of Radio‑Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu 215001, P.R. China
Published online on: October 15, 2019 https://doi.org/10.3892/or.2019.7374
Pages: 2572-2582
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long noncoding RNAs (lncRNAs) have been confirmed to be potential prognostic markers in a variety of cancers and to interact with microRNAs (miRNAs) as competing endogenous RNAs (ceRNAs) to regulate target gene expression. However, the role of lncRNA‑mediated ceRNAs in breast cancer (BC) remains unclear. In the present study, a ceRNA network was generated to explore their role in BC. The expression profiles of mRNAs, miRNAs and lncRNAs in 1,109 BC tissues and 113 normal breast tissues were obtained from The Cancer Genome Atlas database (TCGA). A total of 3,198 differentially expressed (DE) mRNAs, 150 differentially DEmiRNAs and 1,043 DElncRNAs were identified between BC and normal tissues. A lncRNA‑miRNA‑mRNA network associated with BC was successfully constructed based on the combined data obtained from RNA databases, and comprised 97 lncRNA nodes, 24 miRNA nodes and 74 mRNA nodes. The biological functions of the 74 DEmRNAs were further investigated by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. The results demonstrated that the DEmRNAs were significantly enriched in two GO biological process categories; the main biological process enriched term was ‘positive regulation of GTPase activity’. By KEGG analysis, four key enriched pathways were obtained, including the ‘MAPK signaling pathway’, the ‘Ras signaling pathway’, ‘prostate cancer’, and the ‘FoxO signaling pathway’. Kaplan‑Meier survival analysis revealed that six DElncRNAs (INC AC112721.1, LINC00536, MIR7‑3HG, ADAMTS9‑AS1, AL356479.1 and LINC00466), nine DEmRNAs (KPNA2, RACGAP1, SHCBP1, ZNF367, NTRK2, ORS1, PTGS2, RASGRP1 and SFRP1) and two DEmiRNAs (hsa‑miR‑301b and hsa‑miR‑204) had significant effects on overall survival in BC. The present results demonstrated the aberrant expression of INC AC112721.1, AL356479.1, LINC00466 and MIR7‑3HG in BC, indicating their potential prognostic role in patients with BC.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Wang Y, Zhou Y, Yang Z, Chen B, Huang W, Liu Y and Zhang Y: MiR-204/ZEB2 axis functions as key mediator for MALAT1-induced epithelial-mesenchymal transition in breast cancer. Tumour Biol. 39:10104283176909982017. View Article : Google Scholar : PubMed/NCBI
3	Kroenke CH, Michael YL, Poole EM, Kwan ML, Nechuta S, Leas E, Caan BJ, Pierce J, Shu XO, Zheng Y and Chen WY: Postdiagnosis social networks and breast cancer mortality in the after breast cancer pooling project. Cancer. 123:1228–1237. 2017. View Article : Google Scholar : PubMed/NCBI
4	Luschin G and Habersack M: Oral information about side effects of endocrine therapy for early breast cancer patients at initial consultation and first follow-up visit: An online survey. Health Commun. 29:421–426. 2014. View Article : Google Scholar : PubMed/NCBI
5	Cheng Y, Tao L, Xu J, Li Q, Yu J, Jin Y, Chen Q, Xu Z, Zou Q and Liu X: CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients. Mol Carcinog. 53:686–697. 2014. View Article : Google Scholar : PubMed/NCBI
6	Bao L, Messer K, Schwab R, Harismendy O, Pu M, Crain B, Yost S, Frazer KA, Rana B, Hasteh F, et al: Mutational profiling can establish clonal or independent origin in synchronous bilateral breast and other tumors. PLoS One. 10:e01424872015. View Article : Google Scholar : PubMed/NCBI
7	Salmena L, Poliseno L, Tay Y, Kats L and Pandolfi PP: A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
8	Rapicavoli NA, Qu K, Zhang J, Mikhail M, Laberge RM and Chang HY: A mammalian pseudogene lncRNA at the interface of inflammation and anti-inflammatory therapeutics. Elife. 2:e007622013. View Article : Google Scholar : PubMed/NCBI
9	Mercer TR, Dinger ME and Mattick JS: Long non-coding RNAs: Insights into functions. Nat Rev Genet. 10:155–159. 2009. View Article : Google Scholar : PubMed/NCBI
10	Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. Cell. 136:629–641. 2009. View Article : Google Scholar : PubMed/NCBI
11	Anamaria N, Soumillon M, Warnefors M, Liechti A, Daish T, Zeller U, Baker JC, Grützner F and Kaessmann H: The evolution of lncRNA repertoires and expression patterns in tetrapods. Nature. 505:635–640. 2014. View Article : Google Scholar : PubMed/NCBI
12	Xue B and He L: An expanding universe of the non-coding genome in cancer biology. Carcinogenesis. 35:1209–1216. 2014. View Article : Google Scholar : PubMed/NCBI
13	Xie C, Yuan J, Li H, Li M, Zhao G, Bu D, Zhu W, Wu W, Chen R and Zhao Y: NONCODEv4: Exploring the world of long non-coding RNA genes. Nucleic Acids Res. 42((Database Issue)): D98–D103. 2014. View Article : Google Scholar : PubMed/NCBI
14	Kumar M.S..Armenteros-Monterroso E, East P, Chakravorty P, Matthews N, Winslow MM and Downward J: HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature. 505:212–217. 2014. View Article : Google Scholar : PubMed/NCBI
15	Wang C, Chen L, Yang Y, Zhang M and Wong G: Identification of bladder cancer prognostic biomarkers using an ageing gene-related competitive endogenous RNA network. Oncotarget. 8:111742–111753. 2017. View Article : Google Scholar : PubMed/NCBI
16	Zhou M, Wang X, Shi H, Cheng L, Wang Z, Zhao H, Yang L and Sun J: Characterization of long non-coding RNA-associated ceRNA network to reveal potential prognostic lncRNA biomarkers in human ovarian cancer. Oncotarget. 7:12598–12611. 2016.PubMed/NCBI
17	Chiu YC, Hsiao TH, Chen Y and Chuang EY: Parameter optimization for constructing competing endogenous RNA regulatory network in glioblastoma multiforme and other cancers. BMC Genomics. 16 (Suppl 4):S12015. View Article : Google Scholar : PubMed/NCBI
18	Wu Q, Xiang S, Ma J, Hui P, Wang T, Meng W, Shi M and Wang Y: Long non-coding RNA CASC15 regulates gastric cancer cell proliferation, migration and epithelial mesenchymal transition by targeting CDKN1A and ZEB1. Mol Oncol. 12:799–813. 2018. View Article : Google Scholar : PubMed/NCBI
19	Yao K, Wang Q, Jia J and Zhao H: A competing endogenous RNA network identifies novel mRNA, miRNA and lncRNA markers for the prognosis of diabetic pancreatic cancer. Tumour Biol. 39:10104283177078822017. View Article : Google Scholar : PubMed/NCBI
20	Shan Y, Ma J, Pan Y, Hu J, Liu B and Jia L: LncRNA SNHG7 sponges miR-216b to promote proliferation and liver metastasis of colorectal cancer through upregulating GALNT1. Cell Death Dis. 9:7222018. View Article : Google Scholar : PubMed/NCBI
21	Paci P, Colombo T and Farina L: Computational analysis identifies a sponge interaction network between long non-coding RNAs and messenger RNAs in human breast cancer. BMC Syst Biol. 8:832014. View Article : Google Scholar : PubMed/NCBI
22	Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, et al: A comprehensive pan-cancer molecular study of gynecologic and breast cancers. Cancer Cell. 33:690–705.e9. 2018. View Article : Google Scholar : PubMed/NCBI
23	Zhao W, Luo J and Jiao S: Comprehensive characterization of cancer subtype associated long non-coding RNAs and their clinical implications. Sci Rep. 4:65912014. View Article : Google Scholar : PubMed/NCBI
24	Jeggari A, Marks DS and Larsson E: miRcode: A map of putative microRNA target sites in the long non-coding transcriptome. Bioinformatics. 28:2062–2063. 2012. View Article : Google Scholar : PubMed/NCBI
25	Li JH, Liu S, Zhou H, Qu LH and Yang JH: StarBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 42((Database Issue)): D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
26	Wong N and Wang X: miRDB: An online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 43((Database Issue)): D146–D152. 2015. View Article : Google Scholar : PubMed/NCBI
27	Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, Huang WC, Sun TH, Tu SJ, Lee WH, et al: MiRTarBase update 2018: A resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 46:D296–D302. 2018. View Article : Google Scholar : PubMed/NCBI
28	Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. Elife. 4:2015.doi: 10.7554/eLife.05005. View Article : Google Scholar
29	Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
30	Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC and Lempicki RA: DAVID: Database for Annotation, visualization, and Integrated Discovery. Genome Biol. 4:P32003. View Article : Google Scholar : PubMed/NCBI
31	Aiex RM, Resende MGC and Ribeiro CC: TTT plots: A perl program to create time-to-target plots. Optimization Lett. 1:355–366. 2007. View Article : Google Scholar
32	Jia P, Liu Y and Zhao Z: Integrative pathway analysis of genome-wide association studies and gene expression data in prostate cancer. BMC Syst Biol. 6 (Suppl 3):S132012. View Article : Google Scholar : PubMed/NCBI
33	Coomans de Brachène A and Demoulin JB: FOXO transcription factors in cancer development and therapy. Cell Mol Life Sci. 73:1159–1172. 2016. View Article : Google Scholar : PubMed/NCBI
34	Stagl JM, Bouchard LC, Lechner SC, Blomberg BB, Gudenkauf LM, Jutagir DR, Glück S, Derhagopian RP, Carver CS and Antoni MH: Long-term psychological benefits of cognitive-behavioral stress management for women with breast cancer: 11-year follow-up of a randomized controlled trial. Cancer. 121:1873–1881. 2015. View Article : Google Scholar : PubMed/NCBI
35	Haecker I and Renne R: HITS-CLIP and PAR-CLIP advance viral miRNA targetome analysis. Crit Rev Eukaryot Gene Expr. 24:101–116. 2014. View Article : Google Scholar : PubMed/NCBI
36	Wang K, Guo WX, Li N, Gao CF, Shi J, Tang YF, Shen F, Wu MC, Liu SR and Cheng SQ: Serum LncRNAs profiles serve as novel potential biomarkers for the diagnosis of HBV-positive hepatocellular carcinoma. PLoS One. 10:e01449342015. View Article : Google Scholar : PubMed/NCBI
37	Denzler R, Agarwal V, Stefano J, Bartel DP and Stoffel M: Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance. Mol Cell. 54:766–776. 2014. View Article : Google Scholar : PubMed/NCBI
38	Xia T, Liao Q, Jiang X, Shao Y, Xiao B, Xi Y and Guo J: Long noncoding RNA associated-competing endogenous RNAs in gastric cancer. Sci Rep. 4:60882014. View Article : Google Scholar : PubMed/NCBI
39	Liu C, Liu R, Zhang D, Deng Q, Liu B, Chao HP, Rycaj K, Takata Y, Lin K, Lu Y, et al: MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nat Commun. 8:142702017. View Article : Google Scholar : PubMed/NCBI
40	Mikhaylova O, Stratton Y, Hall D, Kellner E, Ehmer B, Drew AF, Gallo CA, Plas DR, Biesiada J, Meller J and Czyzyk-Krzeska MF: VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. Cancer Cell. 21:532–546. 2012. View Article : Google Scholar : PubMed/NCBI
41	Hall DP, Cost NG, Hegde S, Kellner E, Mikhaylova O, Stratton Y, Ehmer B, Abplanalp WA, Pandey R, Biesiada J, et al: TRPM3 and miR-204 establish a regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma. Cancer Cell. 26:738–753. 2014. View Article : Google Scholar : PubMed/NCBI
42	Ying Z, Li Y, Wu J, Zhu X, Yang Y, Tian H, Li W, Hu B, Cheng SY and Li M: Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype. Cancer Res. 73:990–999. 2013. View Article : Google Scholar : PubMed/NCBI
43	Shen SQ, Huang LS, Xiao XL, Zhu XF, Xiong DD, Cao XM, Wei KL, Chen G and Feng ZB: miR-204 regulates the biological behavior of breast cancer MCF-7 cells by directly targeting FOXA1. Oncol Rep. 38:368–376. 2017. View Article : Google Scholar : PubMed/NCBI
44	Fort RS, Mathó C, Oliveira-Rizzo C, Garat B, Sotelo-Silveira JR and Duhagon MA: An integrated view of the role of miR-130b/301b miRNA cluster in prostate cancer. Exp Hematol Oncol. 7:102018. View Article : Google Scholar : PubMed/NCBI
45	Yuan SX, Tao QF, Wang J, Yang F, Liu L, Wang LL, Zhang J, Yang Y, Liu H, Wang F, et al: Antisense long non-coding RNA PCNA-AS1 promotes tumor growth by regulating proliferating cell nuclear antigen in hepatocellular carcinoma. Cancer Lett. 349:87–94. 2014. View Article : Google Scholar : PubMed/NCBI
46	Zhu N, Hou J, Wu Y, Liu J, Li G, Zhao W, Ma G, Chen B and Song Y: Integrated analysis of a competing endogenous RNA network reveals key lncRNAs as potential prognostic biomarkers for human bladder cancer. Medicine (Baltimore). 97:e118872018. View Article : Google Scholar : PubMed/NCBI
47	Xia Y, Liu Z, Yu W, Zhou S, Shao L, Song W and Liu M: The prognostic significance of long noncoding RNAs in bladder cancer: A meta-analysis. PLoS One. 13:e01986022018. View Article : Google Scholar : PubMed/NCBI
48	Xing Y, Zhao Z, Zhu Y, Zhao L, Zhu A and Piao D: Comprehensive analysis of differential expression profiles of mRNAs and lncRNAs and identification of a 14-lncRNA prognostic signature for patients with colon adenocarcinoma. Oncol Rep. 39:2365–2375. 2018.PubMed/NCBI
49	Li Z, Yao Q, Zhao S, Wang Y, Li Y and Wang Z: Comprehensive analysis of differential co-expression patterns reveal transcriptional dysregulation mechanism and identify novel prognostic lncRNAs in esophageal squamous cell carcinoma. Onco Targets Ther. 10:3095–3105. 2017. View Article : Google Scholar : PubMed/NCBI
50	Wang H, Fu Z, Dai C, Cao J, Liu X, Xu J, Lv M, Gu Y, Zhang J, Hua X, et al: LncRNAs expression profiling in normal ovary, benign ovarian cyst and malignant epithelial ovarian cancer. Sci Rep. 6:389832016. View Article : Google Scholar : PubMed/NCBI
51	Sonohara F, Inokawa Y, Hayashi M, Kodera Y and Nomoto S: Epigenetic modulation associated with carcinogenesis and prognosis of human gastric cancer. Oncol Lett. 13:3363–3368. 2017. View Article : Google Scholar : PubMed/NCBI
52	Shi L, Zhang B, Sun X, Lu S, Liu Z, Liu Y, Li H, Wang L, Wang X and Zhao C: MiR-204 inhibits human NSCLC metastasis through suppression of NUAK1. Br J Cancer. 111:2316–2327. 2014. View Article : Google Scholar : PubMed/NCBI
53	Alhawaj R: Heme biosynthesis and metabolism are important contributors to the pathophysiology of chronic hypoxia-induced pulmonary hypertension. Dissertations & Theses-Gradworks, 2014. http://xueshu.baidu.com/usercenter/paper/show?paperid=c770828df9516fbf2613928c9fbecb09&site=xueshu_se&hitarticle=1
54	Liu J and Li Y: Trichostatin A and Tamoxifen inhibit breast cancer cell growth by miR-204 and ERα reducing AKT/mTOR pathway. Biochem Biophys Res Commun. 467:242–247. 2015. View Article : Google Scholar : PubMed/NCBI
55	Vivacqua A, De Marco P, Santolla MF, Cirillo F, Pellegrino M, Panno ML, Abonante S and Maggiolini M: Estrogenic gper signaling regulates mir144 expression in cancer cells and cancer-associated fibroblasts (cafs). Oncotarget. 6:16573–16587. 2015. View Article : Google Scholar : PubMed/NCBI
56	Liu SY, Li XY, Chen WQ, Hu H, Luo B, Shi YX, Wu TW, Li Y, Kong QZ, Lu HD and Lu ZX: Demethylation of the MIR145 promoter suppresses migration and invasion in breast cancer. Oncotarget. 8:61731–61741. 2017.PubMed/NCBI
57	Muti P, Sacconi A, Hossain A, Donzelli S, Ben Moshe NB, Ganci F, Sieri S, Krogh V, Berrino F, Biagioni F, et al: Downregulation of microRNAs 145-3p and 145-5p is a long-term predictor of postmenopausal breast cancer risk: The ORDET prospective study. Cancer Epidemiol Biomarkers Prev. 23:2471–2481. 2014. View Article : Google Scholar : PubMed/NCBI
58	Faraoni I, Antonetti FR, Cardone J and Bonmassar E: miR-155 gene: A typical multifunctional microRNA. Biochim Biophys Acta. 1792:497–505. 2009. View Article : Google Scholar : PubMed/NCBI
59	Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, et al: Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 20:589–599. 2010. View Article : Google Scholar : PubMed/NCBI
60	Chuang MK, Chiu YC, Chou WC, Hou HA, Chuang EY and Tien HF: A 3-microRNA scoring system for prognostication in de novo acute myeloid leukemia patients. Leukemia. 29:1051–1059. 2015. View Article : Google Scholar : PubMed/NCBI
61	Braun R, Finney R, Yan C, Chen QR, Hu Y, Edmonson M, Meerzaman D and Buetow K: Discovery analysis of TCGA data reveals association between germline genotype and survival in ovarian cancer patients. PLoS One. 8:e550372013. View Article : Google Scholar : PubMed/NCBI
62	Yasuda S, Stevens RL, Terada T, Takeda M, Hashimoto T, Fukae J, Horita T, Kataoka H, Atsumi T and Koike T: Defective expression of Ras guanyl nucleotide-releasing protein 1 in a subset of patients with systemic lupus erythematosus. J Immunol. 179:4890–4900. 2007. View Article : Google Scholar : PubMed/NCBI
63	Horinouchi M, Yagi M, Imanishi H, Mori T, Yanai T, Hayakawa A, Takeshima Y, Hijioka M, Okamura N, Sakaeda T, et al: Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma. Pediatr Hematol Oncol. 27:344–354. 2010. View Article : Google Scholar : PubMed/NCBI
64	Depeille P, Henricks LM, van de Ven RA, Lemmens E, Wang CY, Matli M, Werb Z, Haigis KM, Donner D, Warren R and Roose JP: RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. Nat Cell Biol. 17:804–815. 2015. View Article : Google Scholar : PubMed/NCBI
65	Sharma A, Fonseca LL, Rajani C, Yanagida JK, Endo Y, Cline JM, Stone JC, Ji J, Ramos JW and Lorenzo PS: Targeted deletion of RasGRP1 impairs skin tumorigenesis. Carcinogenesis. 35:1084–1091. 2014. View Article : Google Scholar : PubMed/NCBI
66	Zhang X, Zhuang H, Han F, Shao X, Liu Y, Ma X, Wang Z, Qiang Z and Li Y: Sp1-regulated transcription of RasGRP1 promotes HCC proliferation. Liver Int. 38:2006–2017. 2018. View Article : Google Scholar : PubMed/NCBI
67	Wang S, Beeghly-Fadiel A, Cai Q, Cai H, Guo X, Shi L, Wu J, Ye F, Qiu Q, Zheng Y, et al: Gene expression in triple-negative breast cancer in relation to survival. Breast Cancer Res Treat. 171:199–207. 2018. View Article : Google Scholar : PubMed/NCBI
68	Lauchle JO, Kim D, Le DT, Akagi K, Crone M, Krisman K, Warner K, Bonifas JM, Li Q, Coakley KM, et al: Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature. 461:411–414. 2009. View Article : Google Scholar : PubMed/NCBI
69	Ding H, Peterson KL, Correia C, Koh B, Schneider PA, Nowakowski GS and Kaufmann SH: Histone deacetylase inhibitors interrupt HSP90 RASGRP1 and HSP90 CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells. Leukemia. 31:1593–1602. 2017. View Article : Google Scholar : PubMed/NCBI
70	Mortezavi A, Hermanns T, Seifert HH, Baumgartner MK, Provenzano M, Sulser T, Burger M, Montani M, Ikenberg K, Hofstädter F, et al: KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res. 17:1111–1121. 2011. View Article : Google Scholar : PubMed/NCBI
71	Sengel-Turk CT, Hascicek C, Bakar F and Simsek E: Comparative evaluation of nimesulide-loaded nanoparticles for anticancer activity against breast cancer cells. Aaps PharmSciTech. 18:393–403. 2017. View Article : Google Scholar : PubMed/NCBI
72	Hass HG, Vogel U, Scheurlen M and Jobst J: Gene-expression Analysis identifies specific patterns of dysregulated molecular pathways and genetic subgroups of human hepatocellular carcinoma. Anticancer Res. 36:5087–5095. 2016. View Article : Google Scholar : PubMed/NCBI
73	Buhmeida A, Merdad A, Al-Maghrabi J, Al-Thobaiti F, Ata M, Bugis A, Syrjänen K, Abuzenadah A, Chaudhary A, Gari M, et al: RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency. Anticancer Res. 31:2975–2981. 2011.PubMed/NCBI
74	Tao HC, Wang HX, Dai M, Gu CY, Wang Q, Han ZG and Cai B: Targeting SHCBP1 inhibits cell proliferation in human hepatocellular carcinoma cells. Asian Pac J Cancer Prev. 14:5645–5650. 2013. View Article : Google Scholar : PubMed/NCBI
75	Li WX, He K, Tang L, Dai SX, Li GH, Lv WW, Guo YC, An SQ, Wu GY, Liu D and Huang JF: Comprehensive tissue-specific gene set enrichment analysis and transcription factor analysis of breast cancer by integrating 14 gene expression datasets. Oncotarget. 8:6775–6786. 2016.
76	Yang XL, Liu KY, Lin FJ, Shi HM and Ou ZL: CCL28 promotes breast cancer growth and metastasis through MAPK-mediated cellular anti-apoptosis and pro-metastasis. Oncol Rep. 38:1393–1401. 2017. View Article : Google Scholar : PubMed/NCBI
77	Kono M, Fujii T, Lim B, Karuturi MS, Tripathy D and Ueno NT: Androgen receptor function and androgen receptor-targeted therapies in breast cancer: A Review. JAMA Oncol. 3:1266–1273. 2017. View Article : Google Scholar : PubMed/NCBI
78	Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J and Sugimoto Y: Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther. 6:2092–2102. 2007. View Article : Google Scholar : PubMed/NCBI
79	Jia Y, Zhou J, Luo X, Chen M, Chen Y, Wang J, Xiong H, Ying X, Hu W, Zhao W, et al: KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer. Cell Signal. 42:165–175. 2017. View Article : Google Scholar : PubMed/NCBI
80	Serini S and Calviello G: Modulation of Ras/ERK and phosphoinositide signaling by long-chain n-3 PUFA in breast cancer and their potential complementary role in combination with targeted drugs. Nutrients. 9:E1852017. View Article : Google Scholar : PubMed/NCBI
81	Wright KL, Adams JR, Liu JC, Loch AJ, Wong RG, Jo CE, Beck LA, Santhanam DR, Weiss L, Mei X, et al: Ras signaling is a key determinant for metastatic dissemination and poor survival of luminal breast cancer patients. Cancer Res. 75:4960–4972. 2015. View Article : Google Scholar : PubMed/NCBI